What if we could transform the treatment landscape for rheumatologic diseases by taking bold, innovative approaches that go beyond incremental improvements?

In this episode, Dr. James Mackay, CEO of Crystalys Therapeutics, shares the vision behind launching a new biotech company focused on rheumatology, combining next-generation science with strategic leadership to address unmet patient needs.

What we discuss:

• The vision behind Crystalys Therapeutics and why rheumatology

• New approaches and innovative strategies in treating rheumatologic diseases

• Approach to risk management in early-stage biotech

• Fundraising strategies and building investor confidence from day one

• Leadership and culture: assembling the right team for a startup biotech

• Navigating the competitive landscape in rheumatology

• Personal reflections on entrepreneurship and the future of autoimmune disease treatment

This isn't just another rheumatology company. This is about bringing transformative science to patients who desperately need better options.

About the Guest: Dr. James Mackay is CEO of Crystalys Therapeutics, a biotechnology company developing novel therapeutics for rheumatologic diseases.

About the Show: Innovating Tomorrow's Medicine features conversations with biotech leaders, researchers, and innovators who are transforming bold ideas into real-world impact in healthcare and life sciences.

🔗 Connect:

• Crystalys Therapeutics: [https://crystalystx.com]

• James Mackay: [https://www.linkedin.com/in/james-m-mackay]

• Host Jeff Trickett: [https://www.linkedin.com/in/jeff-trickett]

📧 Questions or guest suggestions? [[email protected]]

#Biotech #Rheumatology #AutoimmuneDisease #DrugDevelopment #Innovation #Startup #BiotechLeadership